Skin clearance and route of administration drove treatment choices among 202 patients with psoriasis in the ENCOMPASS-PP discrete choice experiment.
News|Articles|September 23, 2026
Conference Preview: 2026 EADV Congress in Vienna
Author(s)Tim Smith
Fact checked by: Victoria Johnson
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Advertisement
Advertisement
HCPLive will provide on-site coverage of the
Related to this article
Oral prifemilast, a PDE4B-selective inhibitor, led to PASI 75 attainment in up to 57.4% of those with psoriasis at week 16 vs 10.8% with placebo.
Final VALUE data show fewer drug changes with risankizumab vs other biologics over 37 months in patients with psoriasis and comorbid psoriatic arthritis.
In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.
Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.
Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.
Advertisement
Advertisement